Yale Cancer Center Study Shows Novel Test Can Detect New and Recurrent Bladder Cancer

A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.

Yale Cancer Center Study Shows Cognitive Impairment for Survivors of Many Pediatric Cancers

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income. The results were published online today in the Journal of Clinical Oncology (JCO).

Yale Study Shows Combined Liver–Cytokine Humanization Rescues Circulating Red Blood Cells for Testing of Novel Therapeutics

In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in circulation the immunodeficient murine host.

Yale Researchers Identify Tumor Reactive Immune-Cells to help fight against Advanced Melanoma

According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma, a deadly form of skin cancer. The findings were published today in the Journal of Experimental Medicine.

Maryam Lustberg Named Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center

Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as an Associate Professor of Medicine (Medical Oncology).

Dr. Rachel Greenup Appointed Chief of Breast Surgical Oncology at Yale

Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery (Oncology) and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine. In her new role, Dr. Greenup will provide breast surgical oncology leadership across the Smilow Cancer Hospital Network and Care Centers.

Roy S. Herbst, MD, PhD, Receives 2020 ACCC Clinical Research Award

Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.

Yale Cancer Center Study Shows Regional Variation in Genomic Testing for Men with Prostate Cancer

In a new study by Yale Cancer Center, researchers found substantial regional variation in use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies.

Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer

The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.

Dr. Marcella Nunez-Smith Named Director of Center for Community Engagement and Health Equity for Yale Cancer Center and Smilow Cancer Hospital

Marcella Nunez-Smith, MD, MHS, has been appointed Director of the Center for Community Engagement and Health Equity for Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH), as well as Chief Health Equity Officer & Deputy Chief Medical Officer, at SCH, and Associate Cancer Center Director for Community Outreach and Engagement at YCC.

Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer

Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.

Dr. Mehra Golshan Appointed Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center

Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.

Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

Yale Cancer Center launches Center for Community Engagement and Health Equity

Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.

Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers

In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer

Yale Cancer Center researchers show identifying type of chronic pain in adults with sickle cell disease may lead to better outcomes

Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.

Smilow Cancer Hospital expert explains five things you need to know about Lung Cancer

Roy Herbst, M.D., Ph.D., chief of Medical Oncology at Smilow Cancer Hospital, has been researching lung cancer and treating patients with the disease for more than 25 years. He discusses the facts about lung cancer, ways to reduce your risk, and how new treatments are significantly extending life for patients.